Loss of Striatonigral GABAergic Presynaptic Inhibition Enables Motor Sensitization in Parkinsonian Mice

Neuron

Volumn 87, Issue 5, 2015, Pages 976-988

  Borgkvist, Anders ^a   Avegno, Elizabeth M ^a   Wong, Minerva Y ^a   Kheirbek, Mazen A ^b   Sonders, Mark S ^a,b   Hen, Rene ^a   Sulzer, David ^a,b,c  

^a Columbia University ^*  (United States)

^b Department of Medicine   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR; DOPAMINE 1 RECEPTOR; 2,3-DIOXO-6-NITRO-7-SULFAMOYLBENZO(F)QUINOXALINE; 4 AMINOBUTYRIC ACID RECEPTOR; ADRENERGIC RECEPTOR STIMULATING AGENT; AMINO ACID RECEPTOR BLOCKING AGENT; BACTERIAL PROTEIN; CHANNELRHODOPSIN 2, MOUSE; DOPAMINE; FM1 43; GABAERGIC RECEPTOR AFFECTING AGENT; OXIDOPAMINE; PHOTOPROTEIN; PYRIDINIUM DERIVATIVE; QUATERNARY AMMONIUM DERIVATIVE; QUINOXALINE DERIVATIVE; RHODOPSIN; YELLOW FLUORESCENT PROTEIN, BACTERIA;

4 AMINOBUTYRIC ACID RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN NERVE CELL; CONTROLLED STUDY; DENERVATION; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; HEMIPARKINSONIAN; MEDIUM SPINY NEURON; MOTOR PERFORMANCE; MOTOR SENSITIZATION; MOUSE; NERVE PROJECTION; NEUROMODULATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OPTOGENETICS; PARKINSON DISEASE; PARKINSONISM; PRESYNAPTIC INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA PARS COMPACTA; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; INHIBITORY POSTSYNAPTIC POTENTIAL; INJURIES; MEDIAL FOREBRAIN BUNDLE; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SUBSTANTIA NIGRA; SYNAPTOSOME; TRANSGENIC MOUSE;

ADRENERGIC AGENTS; ANIMALS; BACTERIAL PROTEINS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; EXCITATORY AMINO ACID ANTAGONISTS; GABA AGENTS; GABAERGIC NEURONS; GAMMA-AMINOBUTYRIC ACID; HUMANS; INHIBITORY POSTSYNAPTIC POTENTIALS; LUMINESCENT PROTEINS; MEDIAL FOREBRAIN BUNDLE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSONIAN DISORDERS; PRESYNAPTIC TERMINALS; PYRIDINIUM COMPOUNDS; QUATERNARY AMMONIUM COMPOUNDS; QUINOXALINES; RHODOPSIN; SUBSTANTIA NIGRA;

EID: 84940551107     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2015.08.022     Document Type: Article

References (61)

1. Altar C.A., Hauser K. Topography of substantia nigra innervation by D1 receptor-containing striatal neurons. Brain Res. 1987, 410:1-11.
2. Bamford N.S., Robinson S., Palmiter R.D., Joyce J.A., Moore C., Meshul C.K. Dopamine modulates release from corticostriatal terminals. J. Neurosci. 2004, 24:9541-9552.
3. Bamford N.S., Zhang H., Schmitz Y., Wu N.P., Cepeda C., Levine M.S., Schmauss C., Zakharenko S.S., Zablow L., Sulzer D. Heterosynaptic dopamine neurotransmission selects sets of corticostriatal terminals. Neuron 2004, 42:653-663.
4. Bettler B., Tiao J.Y. Molecular diversity, trafficking and subcellular localization of GABAB receptors. Pharmacol. Ther. 2006, 110:533-543.
5. Betz W.J., Bewick G.S. Optical analysis of synaptic vesicle recycling at the frog neuromuscular junction. Science 1992, 255:200-203.
6. Chuhma N., Tanaka K.F., Hen R., Rayport S. Functional connectome of the striatal medium spiny neuron. J. Neurosci. 2011, 31:1183-1192.
7. Connelly W.M., Schulz J.M., Lees G., Reynolds J.N. Differential short-term plasticity at convergent inhibitory synapses to the substantia nigra pars reticulata. J. Neurosci. 2010, 30:14854-14861.
8. Corvol J.C., Muriel M.P., Valjent E., Féger J., Hanoun N., Girault J.A., Hirsch E.C., Hervé D. Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. J. Neurosci. 2004, 24:7007-7014.
9. Deniau J.M., Kitai S.T., Donoghue J.P., Grofova I. Neuronal interactions in the substantia nigra pars reticulata through axon collaterals of the projection neurons. An electrophysiological and morphological study. Exp. Brain Res. 1982, 47:105-113.
10. Deniau J.M., Mailly P., Maurice N., Charpier S. The pars reticulata of the substantia nigra: a window to basal ganglia output. Prog. Brain Res. 2007, 160:151-172.
11. English D.F., Ibanez-Sandoval O., Stark E., Tecuapetla F., Buzsáki G., Deisseroth K., Tepper J.M., Koos T. GABAergic circuits mediate the reinforcement-related signals of striatal cholinergic interneurons. Nat. Neurosci. 2012, 15:123-130.
12. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann. Neurol. 2000, 47:S2-S9. discussion S9-S11.
13. Ferguson S.M., Eskenazi D., Ishikawa M., Wanat M.J., Phillips P.E., Dong Y., Roth B.L., Neumaier J.F. Transient neuronal inhibition reveals opposing roles of indirect and direct pathways in sensitization. Nat. Neurosci. 2011, 14:22-24.
14. Feyder M., Bonito-Oliva A., Fisone G. L-DOPA-induced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission. Front. Behav. Neurosci. 2011, 5:71.
15. Fieblinger T., Graves S.M., Sebel L.E., Alcacer C., Plotkin J.L., Gertler T.S., Chan C.S., Heiman M., Greengard P., Cenci M.A., Surmeier D.J. Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia. Nat. Commun. 2014, 5:5316.
16. Fletcher G.H., Starr M.S. Topography of dopamine behaviours mediated by D1 and D2 receptors revealed by intrastriatal injection of SKF 38393, lisuride and apomorphine in rats with a unilateral 6-hydroxydopamine-induced lesion. Neuroscience 1987, 20:589-597.
17. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci. 1992, 15:133-139.
18. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J., Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990, 250:1429-1432.
19. Grealish S., Mattsson B., Draxler P., Björklund A. Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease. Eur. J. Neurosci. 2010, 31:2266-2278.
20. Guzmán J.N., Hernández A., Galarraga E., Tapia D., Laville A., Vergara R., Aceves J., Bargas J. Dopaminergic modulation of axon collaterals interconnecting spiny neurons of the rat striatum. J. Neurosci. 2003, 23:8931-8940.
21. Harata N., Ryan T.A., Smith S.J., Buchanan J., Tsien R.W. Visualizing recycling synaptic vesicles in hippocampal neurons by FM 1-43 photoconversion. Proc. Natl. Acad. Sci. USA 2001, 98:12748-12753.
22. Hikida T., Kimura K., Wada N., Funabiki K., Nakanishi S. Distinct roles of synaptic transmission in direct and indirect striatal pathways to reward and aversive behavior. Neuron 2010, 66:896-907.
23. Isaacson J.S., Hille B. GABA(B)-mediated presynaptic inhibition of excitatory transmission and synaptic vesicle dynamics in cultured hippocampal neurons. Neuron 1997, 18:143-152.
24. Jackman S.L., Beneduce B.M., Drew I.R., Regehr W.G. Achieving high-frequency optical control of synaptic transmission. J. Neurosci. 2014, 34:7704-7714.
25. Kay A.R., Alfonso A., Alford S., Cline H.T., Holgado A.M., Sakmann B., Snitsarev V.A., Stricker T.P., Takahashi M., Wu L.G. Imaging synaptic activity in intact brain and slices with FM1-43 in C. elegans, lamprey, and rat. Neuron 1999, 24:809-817.
26. Kozlowski M.R., Marshall J.F. Rotation induced by intranigral injections of GABA agonists and antagonists: zone-specific effects. Pharmacol. Biochem. Behav. 1980, 13:561-567.
27. Kravitz A.V., Freeze B.S., Parker P.R., Kay K., Thwin M.T., Deisseroth K., Kreitzer A.C. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 2010, 466:622-626.
28. Kravitz A.V., Tye L.D., Kreitzer A.C. Distinct roles for direct and indirect pathway striatal neurons in reinforcement. Nat. Neurosci. 2012, 15:816-818.
29. Langston J.W., Ballard P. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can. J. Neurol. Sci. 1984, 11(1, Suppl):160-165.
30. Lindgren H.S., Andersson D.R., Lagerkvist S., Nissbrandt H., Cenci M.A. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J. Neurochem. 2010, 112:1465-1476.
31. Mallet N., Ballion B., Le Moine C., Gonon F. Cortical inputs and GABA interneurons imbalance projection neurons in the striatum of parkinsonian rats. J. Neurosci. 2006, 26:3875-3884.
32. Mango D., Bonito-Oliva A., Ledonne A., Nistico R., Castelli V., Giorgi M., Sancesario G., Fisone G., Berretta N., Mercuri N.B. Phosphodiesterase 10A controls D1-mediated facilitation of GABA release from striato-nigral projections under normal and dopamine-depleted conditions. Neuropharmacology 2014, 76:127-136.
33. Marshall J.F., Ungerstedt U. Supersensitivity to apomorphine following destruction of the ascending dopamine neurons: quantification using the rotational model. Eur. J. Pharmacol. 1977, 41:361-367.
34. Mátyás F., Yanovsky Y., Mackie K., Kelsch W., Misgeld U., Freund T.F. Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience 2006, 137:337-361.
35. Meurers B.H., Dziewczapolski G., Shi T., Bittner A., Kamme F., Shults C.W. Dopamine depletion induces distinct compensatory gene expression changes in DARPP-32 signal transduction cascades of striatonigral and striatopallidal neurons. J. Neurosci. 2009, 29:6828-6839.
36. Miyazaki T., Lacey M.G. Presynaptic inhibition by dopamine of a discrete component of GABA release in rat substantia nigra pars reticulata. J. Physiol. 1998, 513:805-817.
37. Morelli M., Fenu S., Garau L., Di Chiara G. Time and dose dependence of the 'priming' of the expression of dopamine receptor supersensitivity. Eur. J. Pharmacol. 1989, 162:329-335.
38. Nadjar A., Gerfen C.R., Bezard E. Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?. Prog. Neurobiol. 2009, 87:1-9.
39. Pons R., Syrengelas D., Youroukos S., Orfanou I., Dinopoulos A., Cormand B., Ormazabal A., Garzía-Cazorla A., Serrano M., Artuch R. Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency. Mov. Disord. 2013, 28:1058-1063.
40. Putterman D.B., Munhall A.C., Kozell L.B., Belknap J.K., Johnson S.W. Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease. J. Pharmacol. Exp. Ther. 2007, 323:277-284.
41. Radnikow G., Misgeld U. Dopamine D1 receptors facilitate GABAA synaptic currents in the rat substantia nigra pars reticulata. J. Neurosci. 1998, 18:2009-2016.
42. Rangel-Barajas C., Silva I., García-Ramírez M., Sánchez-Lemus E., Floran L., Aceves J., Erlij D., Florán B. 6-OHDA-induced hemiparkinsonism and chronic L-DOPA treatment increase dopamine D1-stimulated [(3)H]-GABA release and [(3)H]-cAMP production in substantia nigra pars reticulata of the rat. Neuropharmacology 2008, 55:704-711.
43. Rangel-Barajas C., Silva I., Lopéz-Santiago L.M., Aceves J., Erlij D., Florán B. L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata. Neurobiol. Dis. 2011, 41:51-61.
44. Rick C.E., Lacey M.G. Rat substantia nigra pars reticulata neurones are tonically inhibited via GABAA, but not GABAB, receptors in vitro. Brain Res. 1994, 659:133-137.
45. Robertson G.S., Robertson H.A. Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms. J. Neurosci. 1989, 9:3326-3331.
46. Romo-Parra H., Misgeld U., Yanovsky Y. Regular firing of a single output neuron reduces its own inhibition through endocannabinoids in substantia nigra pars reticulata of juvenile mice. Neuroscience 2009, 160:596-605.
47. Schwarting R.K., Huston J.P. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog. Neurobiol. 1996, 49:215-266.
48. Shen K.Z., Johnson S.W. Presynaptic GABAB and adenosine A1 receptors regulate synaptic transmission to rat substantia nigra reticulata neurones. J. Physiol. 1997, 505:153-163.
49. Svenningsson P., Nishi A., Fisone G., Girault J.A., Nairn A.C., Greengard P. DARPP-32: an integrator of neurotransmission. Annu. Rev. Pharmacol. Toxicol. 2004, 44:269-296.
50. Taverna S., Ilijic E., Surmeier D.J. Recurrent collateral connections of striatal medium spiny neurons are disrupted in models of Parkinson's disease. J. Neurosci. 2008, 28:5504-5512.
51. Tunstall M.J., Oorschot D.E., Kean A., Wickens J.R. Inhibitory interactions between spiny projection neurons in the rat striatum. J. Neurophysiol. 2002, 88:1263-1269.
52. von Krosigk M., Smith Y., Bolam J.P., Smith A.D. Synaptic organization of GABAergic inputs from the striatum and the globus pallidus onto neurons in the substantia nigra and retrorubral field which project to the medullary reticular formation. Neuroscience 1992, 50:531-549.
53. Voon V., Mehta A.R., Hallett M. Impulse control disorders in Parkinson's disease: recent advances. Curr. Opin. Neurol. 2011, 24:324-330.
54. Waddington J.L., Cross A.J. Baclofen and muscimol: behavioural and neurochemical sequelae of unilateral intranigral administration and effects on 3H-GABA receptor binding. Naunyn Schmiedebergs Arch. Pharmacol. 1979, 306:275-280.
55. Wallmichrath I., Szabo B. Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse. Neuroscience 2002, 113:671-682.
56. Warre R., Thiele S., Talwar S., Kamal M., Johnston T.H., Wang S., Lam D., Lo C., Khademullah C.S., Perera G., et al. Altered function of glutamatergic cortico-striatal synapses causes output pathway abnormalities in a chronic model of parkinsonism. Neurobiol. Dis. 2011, 41:591-604.
57. Weintraub D., Nirenberg M.J. Impulse control and related disorders in Parkinson's disease. Neurodegener. Dis. 2013, 11:63-71.
58. Zakharenko S.S., Zablow L., Siegelbaum S.A. Visualization of changes in presynaptic function during long-term synaptic plasticity. Nat. Neurosci. 2001, 4:711-717.
59. Zhang Y.P., Oertner T.G. Optical induction of synaptic plasticity using a light-sensitive channel. Nat. Methods 2007, 4:139-141.
60. Zhou F.W., Jin Y., Matta S.G., Xu M., Zhou F.M. An ultra-short dopamine pathway regulates basal ganglia output. J. Neurosci. 2009, 29:10424-10435.
61. Zucker R.S., Regehr W.G. Short-term synaptic plasticity. Annu. Rev. Physiol. 2002, 64:355-405.